This is a StreetInsider.com Premium Only Page

Corvus Pharma (CRVS) –

Apr 9, 2024 04:01 PM Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Mar 20, 2024 04:38 AM Corvus Pharmaceuticals (CRVS) PT Lowered to $7 at Oppenheimer

Mar 19, 2024 04:09 PM Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 2c

Mar 19, 2024 04:03 PM Form 10-K Corvus Pharmaceuticals, For: Dec 31

Mar 19, 2024 04:02 PM Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 19, 2024 04:02 PM Form 8-K Corvus Pharmaceuticals, For: Mar 19

Mar 13, 2024 04:02 PM Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

Mar 1, 2024 05:57 PM Form 4 Corvus Pharmaceuticals, For: Feb 28 Filed by: Arcara Jeffrey

Feb 14, 2024 01:31 PM Form SC 13G Corvus Pharmaceuticals, Filed by: SAMLYN CAPITAL, LLC

Feb 13, 2024 06:27 PM Form SC 13G/A Corvus Pharmaceuticals, Filed by: MILLER RICHARD A MD

Feb 12, 2024 08:30 AM Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Feb 9, 2024 08:27 AM Mizuho Securities Assumes Corvus Pharmaceuticals (CRVS) at Neutral

Feb 8, 2024 04:27 PM Form 3 Corvus Pharmaceuticals, For: Feb 02 Filed by: Arcara Jeffrey

Feb 8, 2024 04:06 PM Corvus Pharma (CRVS) Granted FDA Orphan Drug Designation for Soquelitinib

Feb 8, 2024 04:05 PM Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

Feb 6, 2024 04:06 PM Corvus Pharma (CRVS) Appoints Jeffrey Arcara as Chief Business Officer

Feb 6, 2024 04:05 PM Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

Jan 23, 2024 05:00 PM Corvus Pharma (CRVS) Announces the Passing of Board Member Edith P. Mitchell

Jan 23, 2024 05:00 PM Form 8-K Corvus Pharmaceuticals, For: Jan 23

Jan 23, 2024 05:00 PM Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

Dec 11, 2023 04:14 AM Corvus Pharma (CRVS) Presents New Interim Soquelitinib Data

Dec 9, 2023 12:00 PM Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

Dec 8, 2023 04:09 PM Form 4 Corvus Pharmaceuticals, For: Dec 06 Filed by: MILLER RICHARD A MD

Dec 8, 2023 04:08 PM Form 4 Corvus Pharmaceuticals, For: Dec 06 Filed by: Jones William Benton

Dec 8, 2023 04:08 PM Form 4 Corvus Pharmaceuticals, For: Dec 06 Filed by: LEA LEIV

Dec 8, 2023 04:07 PM Form 4 Corvus Pharmaceuticals, For: Dec 06 Filed by: Mitchell Edith P.

Dec 8, 2023 04:06 PM Form 4 Corvus Pharmaceuticals, For: Dec 06 Filed by: Grais Linda

Dec 8, 2023 04:05 PM Form 4 Corvus Pharmaceuticals, For: Dec 06 Filed by: CLARK IAN T

Dec 8, 2023 04:04 PM Form 4 Corvus Pharmaceuticals, For: Dec 06 Filed by: Morrison Scott W

Dec 8, 2023 04:03 PM Form 4 Corvus Pharmaceuticals, For: Dec 06 Filed by: Gould Terry P

Dec 8, 2023 04:03 PM Form 4 Corvus Pharmaceuticals, For: Dec 06 Filed by: Thompson Peter A.

Nov 7, 2023 04:15 PM Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q3 EPS

Nov 7, 2023 04:03 PM Form 10-Q Corvus Pharmaceuticals, For: Sep 30

Nov 7, 2023 04:03 PM Form 8-K Corvus Pharmaceuticals, For: Nov 07

Nov 7, 2023 04:01 PM Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Nov 2, 2023 09:15 AM Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

Nov 2, 2023 04:21 AM Corvus Pharma (CRVS) Reports Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib

Nov 1, 2023 07:31 PM Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Oct 31, 2023 04:02 PM Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023

Sep 11, 2023 07:51 AM Corvus Pharmaceuticals (CRVS) PT Raised to $8 at Oppenheimer

Sep 7, 2023 07:35 AM Corvus Pharmaceuticals (CRVS) PT Raised to $8 at Oppenheimer

Sep 7, 2023 06:02 AM Form 8-K Corvus Pharmaceuticals, For: Sep 06

Sep 6, 2023 04:05 PM Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

Aug 18, 2023 07:34 AM Oppenheimer Starts Corvus Pharmaceuticals (CRVS) at Outperform, $7 PT

Aug 8, 2023 04:05 PM Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q2 EPS

Aug 8, 2023 04:03 PM Form 10-Q Corvus Pharmaceuticals, For: Jun 30

Aug 8, 2023 04:01 PM Form 8-K Corvus Pharmaceuticals, For: Aug 08

Aug 8, 2023 04:01 PM Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

Aug 1, 2023 08:30 AM Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

Jul 10, 2023 06:47 AM Corvus Pharmaceuticals (CRVS) PT Raised to $12 at Ladenburg Thalmann